DOCSLIB.ORG

Identification of Novel Regulatory Mechanisms for Cdc42 Gtpase-Activating Protein Cdgap/ARHGAP31, a Protein Involved in Development and Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification of Novel Regulatory Mechanisms for Cdc42 Gtpase-Activating Protein Cdgap/ARHGAP31, a Protein Involved in Development and Cancer Identification of novel regulatory mechanisms for Cdc42 GTPase-activating protein CdGAP/ARHGAP31, a protein involved in development and cancer Ali Ben Djoudi Ouadda Department of Anatomy & Cell Biology McGill University, Montréal, Québec, Canada Submitted October, 2016 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Doctor of Philosophy © Ali Ben Djoudi Ouadda, 2016 Acknowledgments I would like to express my deepest thanks and appreciation to my supervisor, Dr Nathalie Lamarche-Vane, who has opened the door of her laboratory and gave me the opportunity to pursue an excellent research training. Without her kindness, support, guidance and persistent help this thesis would not have been possible. I would like to thank my mentor Dr. Carlos Morales, who has supported, encouraged and guided me with valuable advice from the beginning. I would like also to thank my advisory committee members, Dr. Isabelle Rouiller and Dr. Peter Siegel for their encouragement and precious scientific inputs and feedbacks. I would like to acknowledge the Fonds de Recherche du Québec-Santé (FRSQ) which awarded me a Doctoral Training Scholarship and the McGill Faculty of Medicine/Department of Anatomy & Cell Biology which granted me a Doctoral Internal Scholarship, GREAT Travel and Merit Awards. In addition, a thank you to my colleagues in the Department of Anatomy & Cell Biology, RI-MUHC, IRCM and IRIC for their help and collaboration, either with reagents or scientific discussion and troubleshooting. Special thanks to Martin, Yi and Vilayphone for their precious help and support during my early days in the lab, and to Philippe, Sadig, Fereshteh, Hidetaka, Tristan, Jonathan and Judith for their help, kindness and availability. A special word of thanks goes to my mother Kaissa, and siblings Moussa, Djamila, Ouiza, Zohra, Saida, Djilali, Naima, Hassina and Massinissa for their indefectible support and encouragement. Without their love, patience and sacrifice, I could not have completed this work. I would specifically like to thank my late father Tayeb who assisted and encouraged me throughout my life, and I am sorry that he had not lived to see me complete my Ph.D. Finally, but most importantly, I wish to thank my wife Biba and children Ales and Aya for their love, support, assistance and faith in me. ii | P a g e Abstract The small Rho GTPase proteins act as molecular switches that regulate diverse cellular processes linked mostly to the actin-cytoskeleton remodeling making them essential regulators of cell adhesion, migration and invasion. Dysregulation of their activities can result in different abnormal phenotypes particularly, tumor progression and metastasis. Hence, regulators of Rho GTPases such as Rho guanine nucleotide exchange factors (RhoGEFs) and Rho GTPase-activating proteins (RhoGAPs), are critical for normal cellular responses and are targets for subversion during oncogenic transformation. CdGAP (Cdc42 GTPase-activating protein) is a member of a well-conserved subfamily of RhoGAP proteins and a negative regulator of the small Rho GTPases, Rac1 and Cdc42. Associated with a rare developmental disorder (AOS, Adams-Oliver Syndrome) and required for a normal angiogenesis, CdGAP plays important roles in the regulation of cell migration and proliferation during early development. In addition, recent findings characterize CdGAP as an essential synergistic component between TGFβ and HER2/Neu/ErbB-2 signaling pathways which play a positive role in cancer, particularly breast cancer. CdGAP is regulated by lipid binding, protein-protein interactions and phosphorylation, still these mechanisms are not well understood. In this work we first investigate the interaction between CdGAP and its negative regulator, the endocytic protein Intersectin. Using an in vitro approach, we identify a novel, atypical xKx(K/R) (SKSKK) motif in the basic rich (BR) region of CdGAP that directly interacts with the Intersectin-SH3D domain. Moreover, the well-conserved motif is required for the regulation of CdGAP activity following Intersectin binding. Next, we investigate CdGAP phosphorylation and identify two regulatory phospho-serines in the C-terminal (CT) tail, Ser-1093 and Ser-1163, that are phosphorylated by the AGC-kinase family member, RSK1. Finally, we show that 14-3-3 family members bind and regulate both the cellular localization and activity of CdGAP in a Ser-1093 and Ser-1163 phosphorylation-dependent manner. Overall, this work provides two novel CdGAP- regulatory mechanisms that can be applied in therapeutic approaches targeting this RhoGAP, particularly in breast cancers. iii | P a g e Résumé Les petites protéines G de la famille Rho sont des commutateurs moléculaires qui contrôlent divers procédés cellulaires associés notamment, à la régulation du cytosquelette et jouent par conséquent, un rôle clé dans la régulation de la motilité cellulaire. La dérégulation de leur activité peut entrainer des aberrations se manifestant en particulier, par une progression du cancer et des métastases. Ainsi, les protéines régulatrices comme les facteurs d'échange de nucléotide (RhoGEFs) et les protéines activatrices des Rho GTPases (RhoGAPs) sont essentielles pour une signalisation cellulaire normale et sont en général, affectées lors des transformations oncogéniques. CdGAP (Cdc42-GTPase activating protein) est un membre d’une sous-famille de protéines RhoGAPs bien conservée qui régule négativement les Rho GTPases Cdc42 et Rac1. Associé à un trouble du développement rare, le syndrome d'Adams-Oliver ou AOS et nécessaire pour une angiogenèse normale, CdGAP joue un rôle important dans la régulation de la migration et la prolifération cellulaires au cours du développement. Récemment, CdGAP est identifié comme une composante synergique essentielle entre les voies de signalisation de TGFβ et HER2/Neu/ErbB-2 et qui joue un rôle proto- oncogénique, en particulier dans le cancer du sein. CdGAP est régulée par des mécanismes incluant les lipides, les interactions protéine-protéine et la phosphorylation, néanmoins, ces mécanismes ne sont pas bien élucidés. Dans cette étude, nous étudions en premier l'interaction entre CdGAP et son régulateur négatif, la protéine endocytique, Intersectin. En utilisant une approche in vitro, nous identifions un nouveau motif atypique, xKx (K/R) (SKSKK) dans la région riche en résidus basiques (BR) de CdGAP interagissant directement avec le domaine SH3D d’Intersectin. Le motif est en outre, bien conservé est requis pour la régulation de l'activité CdGAP par Intersectin. Par la suite, nous identifions deux sites de phosphorylation clés dans la région C- terminale de CdGAP, Ser-1093 et Ser-1163 qui sont phosphorylés par la protéine AGC- kinase, RSK1. Nous démontrons finalement, que les protéines adaptatrices 14-3-3 lient et régulent la localisation cellulaire et l’activité de CdGAP d’une manière dépendante de la phosphorylation des résidus, Ser-1093 et Ser-1163. La présente étude identifie deux nouveaux mécanismes de régulation de CdGAP qui peuvent être exploités dans des approches thérapeutiques ciblant cette protéine, notamment dans les cancers du sein. iv | P a g e Table of Contents ACKNOWLEDGEMENTS……………………………………………………………………....ii ABSTRACT…………………………………………………………………….........................iii RÉSUMÉ………………………………………………………………………………………...iv LIST OF TABLES……………………………………………………………………..............viii LIST OF FIGURES…………………………………………………………………….............ix ABBREVIATIONS………………………………………………………………………..…......x CONTRIBUTION OF AUTHORS TO MANUSCRIPTS……………………………………xvi ORIGINAL CONTRIBUTIONS TO KNOWLEDGE…....................................................xviii SUBMITTED MANUSCRIPTS…………………………………………………………….…xix CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW…………………………….1 1.0 General introduction…………………………………………… ………………………….2 1.1 Overview of the small GTPases……………………………………….………………….2 1.1.1 Ras GTPase regulation………………………………………………………………….2 1.1.2 Roles of Ras GTPases……………………………………………………………….….4 1 .2 The Rho GTPase subfamily……………………………………………………………....7 1.2.1 Rho GTPase regulation ………………………………………………………………....7 1.2.1.1 Rho Guanine nucleotide Exchange Factors (RhoGEFs)…………………………..8 1.2.1.2 Rho Guanine nucleotide Dissociation Inhibitors (RhoGDIs)……….………………9 1.2.1.3 Posttranslational regulation……………………………………………………….…..9 1.2.2 Role of Rho GTPases in cancer………………………….……………………………..9 1.3 Rho GTPase-Activating Proteins (RhoGAPs)………………………………………….11 1.3.1 RhoGAP regulation by phosphorylation………………………………………………11 1.3.2 RhoGAP membrane localization………………………………………………………11 1.3.3 RhoGAP role in cancer…………………………………………………………………12 1.4 RhoGAP protein subfamilies……………………………………………………………..13 1.4.1 PH-domain containing RhoGAPs……………………………………………………..18 1.4.2 BAR/FCH-domain containing RhoGAPs……………………………………………..24 1.4.3 C1-domain containing RhoGAPs……………………………………………………...26 1.4.4 SEC14-domain containing RhoGAPs…………………………………………………30 v | P a g e 1.4.5 START-domain containing RhoGAPs………………………………………...………31 1.4.6 Multiple LBD-containing RhoGAPs……………………………………………………33 1.4.7 PBR-containing RhoGAPs.....................................................................................36 1.5 CdGAP regulation and function………………………………………………………….47 1.5.1 Domain organization……………………………………………………………………47 1.5.2 CdGAP regulation…………………………………………………….…………………48 1.5.2.1 Protein-protein interactions…………………………………………………………..48 1.5.2.2 Phosphorylation……………………………………………………………………….48 1.5.2.3 Lipid binding…………………………………………………………………………...49 1.5.3 Cellular functions of CdGAP…………………………………………………………...50
Load more

Recommended publications
  • Regulation of Cdc42 and Its Effectors in Epithelial Morphogenesis Franck Pichaud1,2,*, Rhian F
    © 2019. Published by The Company of Biologists Ltd | Journal of Cell Science (2019) 132, jcs217869. doi:10.1242/jcs.217869 REVIEW SUBJECT COLLECTION: ADHESION Regulation of Cdc42 and its effectors in epithelial morphogenesis Franck Pichaud1,2,*, Rhian F. Walther1 and Francisca Nunes de Almeida1 ABSTRACT An overview of Cdc42 Cdc42 – a member of the small Rho GTPase family – regulates cell Cdc42 was discovered in yeast and belongs to a large family of small – polarity across organisms from yeast to humans. It is an essential (20 30 kDa) GTP-binding proteins (Adams et al., 1990; Johnson regulator of polarized morphogenesis in epithelial cells, through and Pringle, 1990). It is part of the Ras-homologous Rho subfamily coordination of apical membrane morphogenesis, lumen formation and of GTPases, of which there are 20 members in humans, including junction maturation. In parallel, work in yeast and Caenorhabditis elegans the RhoA and Rac GTPases, (Hall, 2012). Rho, Rac and Cdc42 has provided important clues as to how this molecular switch can homologues are found in all eukaryotes, except for plants, which do generate and regulate polarity through localized activation or inhibition, not have a clear homologue for Cdc42. Together, the function of and cytoskeleton regulation. Recent studies have revealed how Rho GTPases influences most, if not all, cellular processes. important and complex these regulations can be during epithelial In the early 1990s, seminal work from Alan Hall and his morphogenesis. This complexity is mirrored by the fact that Cdc42 can collaborators identified Rho, Rac and Cdc42 as main regulators of exert its function through many effector proteins.
    [Show full text]
  • The Proximal Signaling Network of the BCR-ABL1 Oncogene Shows a Modular Organization
    Oncogene (2010) 29, 5895–5910 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc ORIGINAL ARTICLE The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization B Titz, T Low, E Komisopoulou, SS Chen, L Rubbi and TG Graeber Crump Institute for Molecular Imaging, Institute for Molecular Medicine, Jonsson Comprehensive Cancer Center, California NanoSystems Institute, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA BCR-ABL1 is a fusion tyrosine kinase, which causes signaling effects of BCR-ABL1 toward leukemic multiple types of leukemia. We used an integrated transformation. proteomic approach that includes label-free quantitative Oncogene (2010) 29, 5895–5910; doi:10.1038/onc.2010.331; protein complex and phosphorylation profiling by mass published online 9 August 2010 spectrometry to systematically characterize the proximal signaling network of this oncogenic kinase. The proximal Keywords: adaptor protein; BCR-ABL1; phospho- BCR-ABL1 signaling network shows a modular and complex; quantitative mass spectrometry; signaling layered organization with an inner core of three leukemia network; systems biology transformation-relevant adaptor protein complexes (Grb2/Gab2/Shc1 complex, CrkI complex and Dok1/ Dok2 complex). We introduced an ‘interaction direction- ality’ analysis, which annotates static protein networks Introduction with information on the directionality of phosphorylation- dependent interactions. In this analysis, the observed BCR-ABL1 is a constitutively active oncogenic fusion network structure was consistent with a step-wise kinase that arises through a chromosomal translocation phosphorylation-dependent assembly of the Grb2/Gab2/ and causes multiple types of leukemia. It is found in Shc1 and the Dok1/Dok2 complexes on the BCR-ABL1 many cases (B25%) of adult acute lymphoblastic core.
    [Show full text]
  • Mutation-Specific and Common Phosphotyrosine Signatures of KRAS G12D and G13D Alleles Anticipated Graduation August 1St, 2018
    MUTATION-SPECIFIC AND COMMON PHOSPHOTYROSINE SIGNATURES OF KRAS G12D AND G13D ALLELES by Raiha Tahir A dissertation submitted to The Johns Hopkins University in conformity with the requirement of the degree of Doctor of Philosophy Baltimore, MD August 2018 © 2018 Raiha Tahir All Rights Reserved ABSTRACT KRAS is one of the most frequently mutated genes across all cancer subtypes. Two of the most frequent oncogenic KRAS mutations observed in patients result in glycine to aspartic acid substitution at either codon 12 (G12D) or 13 (G13D). Although the biochemical differences between these two predominant mutations are not fully understood, distinct clinical features of the resulting tumors suggest involvement of disparate signaling mechanisms. When we compared the global phosphotyrosine proteomic profiles of isogenic colorectal cancer cell lines bearing either G12D or G13D KRAS mutations, we observed both shared as well as unique signaling events induced by the two KRAS mutations. Remarkably, while the G12D mutation led to an increase in membrane proximal and adherens junction signaling, the G13D mutation led to activation of signaling molecules such as non-receptor tyrosine kinases, MAPK kinases and regulators of metabolic processes. The importance of one of the cell surface molecules, MPZL1, which found to be hyperphosphorylated in G12D cells, was confirmed by cellular assays as its knockdown led to a decrease in proliferation of G12D but not G13D expressing cells. Overall, our study reveals important signaling differences across two common KRAS mutations and highlights the utility of our approach to systematically dissect the subtle differences between related oncogenic mutants and potentially lead to individualized treatments.
    [Show full text]
  • Defining Functional Interactions During Biogenesis of Epithelial Junctions
    ARTICLE Received 11 Dec 2015 | Accepted 13 Oct 2016 | Published 6 Dec 2016 | Updated 5 Jan 2017 DOI: 10.1038/ncomms13542 OPEN Defining functional interactions during biogenesis of epithelial junctions J.C. Erasmus1,*, S. Bruche1,*,w, L. Pizarro1,2,*, N. Maimari1,3,*, T. Poggioli1,w, C. Tomlinson4,J.Lees5, I. Zalivina1,w, A. Wheeler1,w, A. Alberts6, A. Russo2 & V.M.M. Braga1 In spite of extensive recent progress, a comprehensive understanding of how actin cytoskeleton remodelling supports stable junctions remains to be established. Here we design a platform that integrates actin functions with optimized phenotypic clustering and identify new cytoskeletal proteins, their functional hierarchy and pathways that modulate E-cadherin adhesion. Depletion of EEF1A, an actin bundling protein, increases E-cadherin levels at junctions without a corresponding reinforcement of cell–cell contacts. This unexpected result reflects a more dynamic and mobile junctional actin in EEF1A-depleted cells. A partner for EEF1A in cadherin contact maintenance is the formin DIAPH2, which interacts with EEF1A. In contrast, depletion of either the endocytic regulator TRIP10 or the Rho GTPase activator VAV2 reduces E-cadherin levels at junctions. TRIP10 binds to and requires VAV2 function for its junctional localization. Overall, we present new conceptual insights on junction stabilization, which integrate known and novel pathways with impact for epithelial morphogenesis, homeostasis and diseases. 1 National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK. 2 Computing Department, Imperial College London, London SW7 2AZ, UK. 3 Bioengineering Department, Faculty of Engineering, Imperial College London, London SW7 2AZ, UK. 4 Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK.
    [Show full text]
  • CD93 and Dystroglycan Cooperation in Human Endothelial Cell Adhesion and Migration
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 9 CD93 and dystroglycan cooperation in human endothelial cell adhesion and migration Federico Galvagni1,*, Federica Nardi1,*, Marco Maida1, Giulia Bernardini1, Silvia Vannuccini2, Felice Petraglia2, Annalisa Santucci1, Maurizio Orlandini1 1 Department of Biotechnology, Chemistry and Pharmacy, University of Siena, 2-53100 Siena, Italy 2 Department of Molecular and Developmental Medicine, Obstetrics and Gynecology, University of Siena, 53100 Siena, Italy *These authors contributed equally to this work Correspondence to: Maurizio Orlandini, e-mail: [email protected] Keywords: angiogenesis, signal transduction, C1qRp, Src, Cbl Received: June 29, 2015 Accepted: January 22, 2016 Published: February 02, 2016 ABSTRACT CD93 is a transmembrane glycoprotein predominantly expressed in endothelial cells. Although CD93 displays proangiogenic activity, its molecular function in angiogenesis still needs to be clarified. To get molecular insight into the biological role of CD93 in the endothelium, we performed proteomic analyses to examine changes in the protein profile of endothelial cells after CD93 silencing. Among differentially expressed proteins, we identified dystroglycan, a laminin-binding protein involved in angiogenesis, whose expression is increased in vascular endothelial cells within malignant tumors. Using immunofluorescence, FRET, and proximity ligation analyses, we observed a close interaction between CD93 and β-dystroglycan. Moreover, silencing experiments showed that CD93 and dystroglycan promoted endothelial cell migration and organization into capillary-like structures. CD93 proved to be phosphorylated on tyrosine 628 and 644 following cell adhesion on laminin through dystroglycan. This phosphorylation was shown to be necessary for a proper endothelial migratory phenotype. Moreover, we showed that during cell spreading phosphorylated CD93 recruited the signaling protein Cbl, which in turn was phosphorylated on tyrosine 774.
    [Show full text]
  • High Throughput Strategies Aimed at Closing the GAP in Our Knowledge of Rho Gtpase Signaling
    cells Review High Throughput strategies Aimed at Closing the GAP in Our Knowledge of Rho GTPase Signaling Manel Dahmene 1, Laura Quirion 2 and Mélanie Laurin 1,3,* 1 Oncology Division, CHU de Québec–Université Laval Research Center, Québec, QC G1V 4G2, Canada; [email protected] 2 Montréal Clinical Research Institute (IRCM), Montréal, QC H2W 1R7, Canada; [email protected] 3 Université Laval Cancer Research Center, Québec, QC G1R 3S3, Canada * Correspondence: [email protected] Received: 21 May 2020; Accepted: 7 June 2020; Published: 9 June 2020 Abstract: Since their discovery, Rho GTPases have emerged as key regulators of cytoskeletal dynamics. In humans, there are 20 Rho GTPases and more than 150 regulators that belong to the RhoGEF, RhoGAP, and RhoGDI families. Throughout development, Rho GTPases choregraph a plethora of cellular processes essential for cellular migration, cell–cell junctions, and cell polarity assembly. Rho GTPases are also significant mediators of cancer cell invasion. Nevertheless, to date only a few molecules from these intricate signaling networks have been studied in depth, which has prevented appreciation for the full scope of Rho GTPases’ biological functions. Given the large complexity involved, system level studies are required to fully grasp the extent of their biological roles and regulation. Recently, several groups have tackled this challenge by using proteomic approaches to map the full repertoire of Rho GTPases and Rho regulators protein interactions. These studies have provided in-depth understanding of Rho regulators specificity and have contributed to expand Rho GTPases’ effector portfolio. Additionally, new roles for understudied family members were unraveled using high throughput screening strategies using cell culture models and mouse embryos.
    [Show full text]
  • NCK1 Antibody (Monoclonal) (M01) Mouse Monoclonal Antibody Raised Against a Partial Recombinant NCK1
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 NCK1 Antibody (monoclonal) (M01) Mouse monoclonal antibody raised against a partial recombinant NCK1. Catalog # AT2980a Specification NCK1 Antibody (monoclonal) (M01) - Product Information Application WB, E Primary Accession P16333 Other Accession BC006403 Reactivity Human Host mouse Clonality Monoclonal Isotype IgG1 Kappa Calculated MW 42864 NCK1 Antibody (monoclonal) (M01) - Additional Information Antibody Reactive Against Recombinant Protein.Western Blot detection against Gene ID 4690 Immunogen (37.73 KDa) . Other Names Cytoplasmic protein NCK1, NCK adaptor protein 1, Nck-1, SH2/SH3 adaptor protein NCK-alpha, NCK1, NCK Target/Specificity NCK1 (AAH06403, 185 a.a. ~ 294 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. Dilution WB~~1:500~1000 Format Clear, colorless solution in phosphate NCK1 monoclonal antibody (M01), clone 1A1 buffered saline, pH 7.2 . Western Blot analysis of NCK1 expression in Hela S3 NE ( (Cat # AT2980a ) Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. Precautions NCK1 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. NCK1 Antibody (monoclonal) (M01) - Protocols Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Provided below are standard protocols that you may find useful for product applications. • Western Blot • Blocking Peptides • Dot Blot • Immunohistochemistry • Immunofluorescence • Immunoprecipitation • Flow Cytomety • Cell Culture Western Blot analysis of NCK1 expression in transfected 293T cell line by NCK1 monoclonal antibody (M01), clone 1A1.
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Supp Table 6.Pdf
    Supplementary Table 6. Processes associated to the 2037 SCL candidate target genes ID Symbol Entrez Gene Name Process NM_178114 AMIGO2 adhesion molecule with Ig-like domain 2 adhesion NM_033474 ARVCF armadillo repeat gene deletes in velocardiofacial syndrome adhesion NM_027060 BTBD9 BTB (POZ) domain containing 9 adhesion NM_001039149 CD226 CD226 molecule adhesion NM_010581 CD47 CD47 molecule adhesion NM_023370 CDH23 cadherin-like 23 adhesion NM_207298 CERCAM cerebral endothelial cell adhesion molecule adhesion NM_021719 CLDN15 claudin 15 adhesion NM_009902 CLDN3 claudin 3 adhesion NM_008779 CNTN3 contactin 3 (plasmacytoma associated) adhesion NM_015734 COL5A1 collagen, type V, alpha 1 adhesion NM_007803 CTTN cortactin adhesion NM_009142 CX3CL1 chemokine (C-X3-C motif) ligand 1 adhesion NM_031174 DSCAM Down syndrome cell adhesion molecule adhesion NM_145158 EMILIN2 elastin microfibril interfacer 2 adhesion NM_001081286 FAT1 FAT tumor suppressor homolog 1 (Drosophila) adhesion NM_001080814 FAT3 FAT tumor suppressor homolog 3 (Drosophila) adhesion NM_153795 FERMT3 fermitin family homolog 3 (Drosophila) adhesion NM_010494 ICAM2 intercellular adhesion molecule 2 adhesion NM_023892 ICAM4 (includes EG:3386) intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)adhesion NM_001001979 MEGF10 multiple EGF-like-domains 10 adhesion NM_172522 MEGF11 multiple EGF-like-domains 11 adhesion NM_010739 MUC13 mucin 13, cell surface associated adhesion NM_013610 NINJ1 ninjurin 1 adhesion NM_016718 NINJ2 ninjurin 2 adhesion NM_172932 NLGN3 neuroligin
    [Show full text]
  • Systematic Name Gene Name Systematic Name Gene Name NM 001710 Complement Factor B(CFB) NM 052831 Solute Carrier Family 18 Member
    Table S1: Genome-wide identification of SGLT2i`s interaction with early inflammatory response in human proximal tubular cells. Systematic Systematic Gene Name Gene Name Name Name solute carrier family 18 member NM_001710 complement factor B(CFB) NM_052831 B1(SLC18B1) heterogeneous nuclear DAZ associated protein NM_031372 NM_170711 ribonucleoprotein D like(HNRNPDL) 1(DAZAP1) NM_014299 bromodomain containing 4(BRD4) NM_001261 cyclin dependent kinase 9(CDK9) cilia and flagella associated protein NM_182628 NM_178835 zinc finger protein 827(ZNF827) 100(CFAP100) NM_017906 PAK1 interacting protein 1(PAK1IP1) NM_024015 homeobox B4(HOXB4) family with sequence similarity 167 ankyrin repeat and LEM domain NM_053279 NM_015114 member A(FAM167A) containing 2(ANKLE2) small cell adhesion ARP3 actin related protein 3 NM_001031628 NM_005721 glycoprotein(SMAGP) homolog(ACTR3) TRAF3 interacting protein actin related protein 2/3 complex NM_147686 NM_005720 2(TRAF3IP2) subunit 1B(ARPC1B) basic leucine zipper ATF-like cAMP responsive element binding NM_018664 NM_182898 transcription factor 3(BATF3) protein 5(CREB5) zinc finger CCCH-type containing activation induced cytidine NM_025079 NM_020661 12A(ZC3H12A) deaminase(AICDA) C-X-C motif chemokine ligand DENN domain containing NM_001511 NM_015213 1(CXCL1) 5A(DENND5A) NM_025072 prostaglandin E synthase 2(PTGES2) NM_004665 vanin 2(VNN2) superoxide dismutase 2, mitochondrial ribosomal protein NM_001024465 NM_016070 mitochondrial(SOD2) S23(MRPS23) jumonji and AT-rich interaction NM_033199 urocortin 2(UCN2) NM_004973
    [Show full text]
  • A Genome-Wide Association Study Identifies Multiple Regions
    GENOMIC SELECTION A Genome-Wide Association Study Identifies Multiple Regions Associated with Head Size in Catfish Xin Geng,* Shikai Liu,* Jun Yao,* Lisui Bao,* Jiaren Zhang,* Chao Li,* Ruijia Wang,* Jin Sha,§ † ‡ Peng Zeng, Degui Zhi, ,** and Zhanjiang Liu*,1 *Fish Molecular Genetics and Biotechnology Laboratory, Aquatic Genomics Unit, School of Fisheries, Aquaculture and § Aquatic Sciences, †Department of Mathematics and Statistics, Auburn University, Alabama 36849, Department of Biostatistics, University of Alabama at Birmingham, Alabama 35294, and ‡School of Biomedical Informatics and **School of Public Health, the University of Texas Health Science Center at Houston, Texas 77030 ABSTRACT Skull morphology is fundamental to evolution and the biological adaptation of species to their KEYWORDS environments. With aquaculture fish species, head size is also important for economic reasons because it head size has a direct impact on fillet yield. However, little is known about the underlying genetic basis of head size. GWAS Catfish is the primary aquaculture species in the United States. In this study, we performed a genome-wide QTL association study using the catfish 250K SNP array with backcross hybrid catfish to map the QTL for head fish size (head length, head width, and head depth). One significantly associated region on linkage group (LG) hybrid 7 was identified for head length. In addition, LGs 7, 9, and 16 contain suggestively associated regions for GenPred head length. For head width, significantly associated regions were found on LG9, and additional shared data suggestively associated regions were identified on LGs 5 and 7. No region was found associated with resources head depth. Head size genetic loci were mapped in catfish to genomic regions with candidate genes genomic involved in bone development.
    [Show full text]
  • 1 Gain-Of-Function Mutations of ARHGAP31, a Cdc42/Rac1
    Gain-of-Function Mutations of ARHGAP31, a Cdc42/Rac1 GTPase Regulator, Cause Syndromic Cutis Aplasia and Limb Anomalies Laura Southgate,1,12 Rajiv D. Machado,1,12 Katie M. Snape,1,12 Martin Primeau,2 Dimitra Dafou,1 Deborah M. Ruddy,3 Peter A. Branney,4 Malcolm Fisher,4 Grace J. Lee,1 Michael A. Simpson,1 Yi He,2 Teisha Y. Bradshaw,1 Bettina Blaumeiser,5 William S. Winship,6 Willie Reardon,7 Eamonn R. Maher,8,9 David R. FitzPatrick,4 Wim Wuyts,5 Martin Zenker,10,11 Nathalie Lamarche-Vane2 and Richard C. Trembath1,3,* Author affiliations: 1King’s College London, Department of Medical and Molecular Genetics, School of Medicine, Guy’s Hospital, London, SE1 9RT, United Kingdom; 2McGill University, Department of Anatomy and Cell Biology, 3640 University Street, Montreal, Quebec, Canada; 3Department of Clinical Genetics, Guy’s Hospital, London, SE1 9RT, United Kingdom; 4MRC Human Genetics Unit, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, United Kingdom; 5Department of Medical Genetics, University and University Hospital of Antwerp, Prins Boudewijnlaan 43, 2650 Edegem, Belgium; 6Nelson R Mandela School of Medicine, Faculty of Health Sciences, Department of Paediatrics and Child Health, University of KwaZulu-Natal, Durban 4041, South Africa; 7National Centre for Medical Genetics, Our Lady's Hospital for Sick Children, Crumlin, Dublin 12, Ireland; 8Medical and Molecular Genetics, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Institute of Biomedical Research, Birmingham, B15 2TT, United Kingdom; 9West Midlands Regional Genetics Service, Birmingham Women's Hospital, Birmingham, B15 2TG, United Kingdom; 10Institute of Human Genetics, University Hospital Erlangen, University of Erlangen- Nuremberg, Schwabachanlage 10, 91054, Erlangen, Germany; 11Institute of Human Genetics, University Hospital Magdeburg, Leipziger Str.
    [Show full text]